# Public Health

**Accelerating global vaccination coverage of frontline workers and populations at-risk of severe COVID-19 complications**

---Manuscript Draft---

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>PUHE-D-21-00197</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article Type:</td>
<td>Letter to the Editor</td>
</tr>
<tr>
<td>Keywords:</td>
<td></td>
</tr>
</tbody>
</table>
| Corresponding Author: | Jonny Currie  
Division of Population Medicine  
Cardiff, UNITED KINGDOM |
| First Author:      | Jonny Currie, MBChB MPH MRCP(UK) MFPH MAcadMEd |
| Order of Authors:  | Jonny Currie, MBChB MPH MRCP(UK) MFPH MAcadMEd  
Luke Allen, MBChB MPH  
Steven Senior, PhD MFPH  
Rory Honney, BM BCh MA(Oxon) MScPH MRCP(London) MRCGP(UK) MFPH  
Anyá Göpfert, MBBS BSc  
Mike Kalmus Eliasz, MBBS MSc |
| Abstract:          |                  |
| Suggested Reviewers: | None None  
none@none.com  
None1 None1  
none@none.com |

Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
COVID-19 vaccination campaigns are well underway in many countries, however a number of governments have committed to vaccinating their entire adult populations before releasing pre-purchased doses for other countries. With limited doses available in 2021, this strategy will result in rich low-risk individuals receiving jabs with marginal benefit ahead of front-line health workers and high-risk populations in low-income countries.

Researchers at North-eastern University have estimated that international cooperation to distribute available vaccine doses according to population size and clinical need could cut global deaths by half, in comparison to the competitive scenario where rich countries monopolise early doses for their own populations.

While we recognise the domestic political imperatives at play, the competitive atmosphere in which deals are being made by individual governments directly contravenes the spirit that is needed to achieve a coordinated global recovery, and potentially even harms the self-interests of individual governments and their populations. As increasing numbers of vaccine candidates receive approval, many wealthy countries are in the position of having more doses of effective vaccines on order than are needed to vaccinate their own populations. The potential hoarding of vaccine orders by some countries creates a number of risks, not only to countries that are deprived of vaccines, but also to the countries that hold more orders than they need.

First, failing to achieve control of COVID-19 in countries of the global south is likely to stymie any global economic recovery which from previous financial crises is recognised to be precarious in itself. The World Bank among others has highlighted the need for coordination in halting circulation of the SARS-CoV-2 virus in all regions of the world or else risk a heavily subdued recovery. Global markets and supply chains mean few countries can see a strong rebound alone.

Second, virologists and epidemiologists have already highlighted the risk of endemic circulation particularly with the potential for selective pressures of vaccines and treatments on further mutations of the virus. Uncontrolled circulation in any region of the world risks re-introduction of infection and possibly of mutated strains that may affect virulence, vaccine efficacy or transmissibility.

Thirdly, adequate human resources for health are vital in responding to pandemics and to ensuring global health security, as shown by the Ebola epidemic. Although fortunately mortality in many low income countries has been low in the first wave the pandemic is exacerbating existing health worker shortages. Countries such as Niger, which has 1 doctor per 20,000 people, has had relatively few COVID-19 deaths but 19% of detected cases have been in health workers.

Finally, there is a clear question also of vaccine equity. Is it morally justifiable to commence population-wide vaccination drives in rich countries when health workers and vulnerable populations in low-income countries have not been afforded access? Do lives in one part of the world intrinsically matter more than in another?

There is undeniably an opportunity to rebuild from this pandemic a fairer and more just world than the one the virus first appeared in. To do so governments should avoid further bilateral and direct procurement from vaccine manufacturers and instead pool resources to achieve equitable, global distribution and delivery. This should include relinquishing any excess advance orders for vaccines that countries no longer need.

This could include increased pledges to COVAX, the GAVI/WHO platform for COVID-19 vaccines, distribution of existing purchases and stock to populations in-need overseas,
health system strengthening in low- and middle-income countries to aid vaccine delivery and even application of WTO trade rules to waive patent protection and allow generic vaccine production at-cost.

No one is safe until everyone is safe – policymakers and those able to influence decisions surrounding vaccine procurement, manufacturing and distribution need to understand the implications of our current strategy and see the benefits of one that better prioritises social justice and health equity.

References

4- Dyer Owen. Covid-19: No large hidden outbreak in Africa but health worker shortage worsens BMJ 2020; 370 :m2685
Accelerating global vaccination coverage of frontline workers and populations at-risk of severe COVID-19 complications

Dr Jonny Currie, Public health and primary care doctor, South East Wales
Fairview St Hilary Vale of Glamorgan Wales CF71 7DR
Jonny.currie@wales.nhs.uk

Dr Luke Allen, Director, Healthier Systems
Dr Rory Honney, Primary Care & Public Health Doctor; Trustee, Health Poverty Action
Dr Mike Kalmus Eliaz, Academic Clinical Fellow in Global Child Health, University of Liverpool
Dr Steven Senior, Visiting Lecturer, University of Manchester

Declarations of interest: None.